Table 2 PCA results.

From: Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

 

Tau pathology/Degeneration

Injury/Inflammation

Aβ Pathology

Non-AD Inflammation

Non-AD Synaptic functioning

 

EMIF

ADNI

Mega

EMIF

ADNI

Mega

EMIF

ADNI

Mega

EMIF

ADNI

Mega

EMIF

ADNI

Mega

Loadings

Tau

0.84

0.91

0.86

0.25

0.19

0.23

−0.06

−0.04

−0.05

0.28

0.23

0.27

0.27

0.26

0.28

pTau

0.91

0.93

0.92

0.10

0.14

0.11

−0.05

−0.14

−0.07

0.16

0.20

0.17

0.26

0.23

0.26

Aβ

−0.06

−0.09

−0.07

−0.05

−0.04

−0.04

1.00

1.00

1.00

−0.05

−0.01

−0.04

0.03

0.02

0.03

NfL

0.19

0.19

0.19

0.94

0.95

0.94

−0.05

−0.04

−0.05

0.25

0.25

0.25

0.10

0.07

0.09

YKL−40

0.31

0.28

0.31

0.31

0.28

0.30

−0.06

−0.01

−0.05

0.88

0.91

0.89

0.18

0.10

0.16

Ng

0.45

0.57

0.48

0.12

0.09

0.11

0.05

0.04

0.05

0.19

0.13

0.18

0.86

0.80

0.85

R2

0.32

0.36

0.33

0.18

0.17

0.18

0.17

0.17

0.17

0.17

0.17

0.17

0.16

0.13

0.15

MMSE correlation

−0.21

−0.15

−0.19

−0.25

−0.15

−0.22

0.33

0.13

0.28

−0.07

−0.01

−0.05

−0.02

0.01

−0.02

  1. R2 Variance explained by component.
  2. MMSE correlation Spearman correlation between principal component and MMSE scores. MMSE scores were residualized for age, sex, and genetic ancestry.
  3. Principal component analysis of CSF biomarkers per study (EMIF/ADNI) and across studies (Mega). Component loadings of each biomarker (first column) on five principal components (column groups two to six) are displayed in order of the component’s explained variance (R2). Analyses are based on 480 participants (EMIF: 353, ADNI: 127).
Back to article page